The Silly Season Passed Us By
This article was originally published in RAJ Devices
In news circles, summer is traditionally known as “the silly season”, where, in the absence of hard news, journalists are reduced to reporting on matters that would usually never make it into print. Not this year, at least not as far as the world of medical device regulatory affairs was concerned.
You may also be interested in...
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.